Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study

IF 9 2区 医学 Q1 ORTHOPEDICS Osteoarthritis and Cartilage Pub Date : 2025-01-22 DOI:10.1016/j.joca.2024.12.010
Minerva Nong , Medha Barbhaiya , Genna Braverman , Vivian P. Bykerk , Nathaniel Hupert , Colby Lewis V , Lisa A. Mandl
{"title":"Association of COVID-19 vaccinations with osteoarthritis flares: A case-crossover study","authors":"Minerva Nong ,&nbsp;Medha Barbhaiya ,&nbsp;Genna Braverman ,&nbsp;Vivian P. Bykerk ,&nbsp;Nathaniel Hupert ,&nbsp;Colby Lewis V ,&nbsp;Lisa A. Mandl","doi":"10.1016/j.joca.2024.12.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>People with osteoarthritis (OA) commonly experience flares. Whether COVID-19 vaccination triggers OA flares is unknown.</div></div><div><h3>Design</h3><div>Adults with OA enrolled in a COVID-19 Rheumatology Registry were invited to participate in a case-crossover study. Vaccine data were ascertained from self-report and electronic health records (EHR). OA was identified using coding algorithms and validated via EHR. Participants reported flare and non-flare periods. Vaccine exposures in the 2-, 7-, and 14-day “lookback windows” prior to OA flares were compared to vaccine exposures during similar non-flare (“control”) periods.</div></div><div><h3>Results</h3><div>279 participants had validated OA, and 136 (49%) contributed at least one flare and one control period. Mean age was 68 years [SD ±8], 82% female, 87% White, 62% knee OA, 56% hip OA, 37% hand/wrist OA and 60% had &gt;= one anatomic location of OA. 525 COVID-19 vaccine doses were recorded, and participants reported 374 OA flares: 30% were mild, 55% were moderate, and 14% were severe. OA flares were not associated with COVID-19 vaccination 2 or 7 days prior (odds ratios [OR] 0.69 [95% confidence interval (CI): 0.28, 1.66], OR 0.54 [95% CI: 0.27, 1.07], respectively). In the 14-day lookback window, fewer flares occurred after vaccination (OR 0.57 [95% CI: 0.34, 0.97], p=0.039). Analyses stratified on sex, age, knee or hand OA, vaccine brand, and dose showed no increased association between COVID-19 vaccination and OA flares.</div></div><div><h3>Conclusion</h3><div>The lack of positive association between COVID-19 vaccination and OA flare in any primary or secondary analysis provides reassurance regarding the use of COVID-19 vaccines in people with OA.</div></div>","PeriodicalId":19654,"journal":{"name":"Osteoarthritis and Cartilage","volume":"33 4","pages":"Pages 500-508"},"PeriodicalIF":9.0000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoarthritis and Cartilage","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1063458425000196","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

People with osteoarthritis (OA) commonly experience flares. Whether COVID-19 vaccination triggers OA flares is unknown.

Design

Adults with OA enrolled in a COVID-19 Rheumatology Registry were invited to participate in a case-crossover study. Vaccine data were ascertained from self-report and electronic health records (EHR). OA was identified using coding algorithms and validated via EHR. Participants reported flare and non-flare periods. Vaccine exposures in the 2-, 7-, and 14-day “lookback windows” prior to OA flares were compared to vaccine exposures during similar non-flare (“control”) periods.

Results

279 participants had validated OA, and 136 (49%) contributed at least one flare and one control period. Mean age was 68 years [SD ±8], 82% female, 87% White, 62% knee OA, 56% hip OA, 37% hand/wrist OA and 60% had >= one anatomic location of OA. 525 COVID-19 vaccine doses were recorded, and participants reported 374 OA flares: 30% were mild, 55% were moderate, and 14% were severe. OA flares were not associated with COVID-19 vaccination 2 or 7 days prior (odds ratios [OR] 0.69 [95% confidence interval (CI): 0.28, 1.66], OR 0.54 [95% CI: 0.27, 1.07], respectively). In the 14-day lookback window, fewer flares occurred after vaccination (OR 0.57 [95% CI: 0.34, 0.97], p=0.039). Analyses stratified on sex, age, knee or hand OA, vaccine brand, and dose showed no increased association between COVID-19 vaccination and OA flares.

Conclusion

The lack of positive association between COVID-19 vaccination and OA flare in any primary or secondary analysis provides reassurance regarding the use of COVID-19 vaccines in people with OA.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19疫苗接种与骨关节炎发作的关联:一项病例交叉研究
目的:骨关节炎(OA)患者通常会出现耀斑。COVID-19疫苗接种是否会引发OA发作尚不清楚。设计:在COVID-19风湿病登记处登记的OA成人被邀请参加一项病例交叉研究。通过自我报告和电子健康记录(EHR)确定疫苗数据。使用编码算法识别OA,并通过电子病历进行验证。参与者报告了耀斑期和非耀斑期。将OA发作前2天、7天和14天的“回望窗口”中的疫苗暴露与类似的非发作(“对照”)期间的疫苗暴露进行比较。结果:279名参与者证实了OA, 136名(49%)至少有一次发作和一个控制期。平均年龄68岁[SD±8],82%为女性,87%为白人,62%为膝关节OA, 56%为髋部OA, 37%为手/腕部OA, 60%为>= OA的一个解剖位置。记录了525次COVID-19疫苗剂量,参与者报告了374次OA发作:30%为轻度,55%为中度,14%为重度。OA发作与2或7天前接种COVID-19疫苗无关(or分别为0.69 [95% CI: 0.28, 1.66], or为0.54 [95% CI: 0.27, 1.07])。在14天的回顾窗口中,接种疫苗后发生的耀斑较少(OR 0.57 [95% CI: 0.34, 0.97], p=0.039)。对性别、年龄、膝关节或手部OA、疫苗品牌和剂量进行分层分析显示,COVID-19疫苗接种与OA发作之间没有增加的关联。结论:在任何一级或二级分析中,COVID-19疫苗接种与OA发作之间缺乏正相关,这为OA患者使用COVID-19疫苗提供了保证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Osteoarthritis and Cartilage
Osteoarthritis and Cartilage 医学-风湿病学
CiteScore
11.70
自引率
7.10%
发文量
802
审稿时长
52 days
期刊介绍: Osteoarthritis and Cartilage is the official journal of the Osteoarthritis Research Society International. It is an international, multidisciplinary journal that disseminates information for the many kinds of specialists and practitioners concerned with osteoarthritis.
期刊最新文献
Blind spots in reporting and representation in knee osteoarthritis research: A systematic review of the sociodemographic and clinical characteristics of 22,443 participants in randomised controlled trials of first-line care. Digital mobility measures in osteoarthritis: endpoint innovation without losing what matters. A timely assessment of the state of transcriptomic and epigenomic profiling in OA: Opportunities for advancements. Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of human developmental dysplasia of the hip. Computational translation of mouse models of osteoarthritis predicts human disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1